Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
Vega-Garcia N, Benito R, Esperanza-Cebollada E, Llop M, Robledo C, Vicente-Garcés C, Alonso J, Barragán E, Fernández G, Hernández-Sánchez JM, Martín-Izquierdo M, Maynou J, Minguela A, Montaño A, Ortega M, Torrebadell M, Cervera J, Sánchez J, Jiménez-Velasco A, Riesco S, Hernández-Rivas JM, Lassaletta Á, Fernández JM, Rives S, Dapena JL, Ramírez M, Camós M, On Behalf Of The Group Of Leukemia Of The Spanish Society Of Pediatric Hematology And Oncology Sehop. Vega-Garcia N, et al. Among authors: dapena jl. J Pers Med. 2020 Nov 26;10(4):244. doi: 10.3390/jpm10040244. J Pers Med. 2020. PMID: 33255984 Free PMC article.
Asparaginase use for the treatment of acute lymphoblastic leukemia.
Barba P, Dapena JL, Montesinos P, Rives S. Barba P, et al. Among authors: dapena jl. Med Clin (Barc). 2017 Mar 3;148(5):225-231. doi: 10.1016/j.medcli.2016.12.006. Epub 2017 Jan 22. Med Clin (Barc). 2017. PMID: 28118965 Review. English, Spanish. No abstract available.
ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain.
Bautista F, Cañete A, Ramírez-Villar GL, Fernández JM, Fuster JL, Diaz de Heredia C, Astigarraga I, García-Ariza M, Rives S, Dapena JL, Márquez C, Molinés A, Bermúdez MDM, Gallego S, Andrés MDM, Verdu-Amoros J, Hernández C, López M, Catalá A, Lassaletta Á, Cruz O, Ramírez M, Lendínez F, Carboné A, Gomez Sirvent J, Tallón M, Acha T, Moreno L, Fernández-Teijeiro A; Sociedad Española de Hematología y Oncología Pediátrica (SEHOP). Bautista F, et al. Among authors: dapena jl. Clin Transl Oncol. 2019 Dec;21(12):1763-1770. doi: 10.1007/s12094-019-02221-9. Epub 2019 Oct 9. Clin Transl Oncol. 2019. PMID: 31598904 Free article.
Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
Fuster JL, Molinos-Quintana A, Fuentes C, Fernández JM, Velasco P, Pascual T, Rives S, Dapena JL, Sisinni L, López-Godino O, Palomo P, Villa-Alcázar M, Bautista F, González-Vicent M, López-Duarte M, García-Morín M, Ramos-Elbal E, Ramírez M; Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP). Fuster JL, et al. Among authors: dapena jl. Br J Haematol. 2020 Sep;190(5):764-771. doi: 10.1111/bjh.16647. Epub 2020 Apr 21. Br J Haematol. 2020. PMID: 32314348 Free article.
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic.
Faura A, Rives S, Lassaletta Á, Sebastián E, Madero L, Huerta J, García-Morín M, Martínez AP, Sisinni L, Astigarraga I, Velasco P, Gros L, Moreno L, Carboné A, Rodríguez-Vigil C, Riesco S, Mendoza MDC, Macias EG, Trabazo M, Torrent M, Badell I, Fuster JL, Dominguez-Pinilla N, Juan Ribelles A, Pérez-Alonso V, Fernández Sanmartín M, Baragaño M, Gorostegui M, Perez-Jaume S, Fernández-Teijeiro A, Morales La Madrid A, Dapena JL. Faura A, et al. Among authors: dapena jl. Pediatr Blood Cancer. 2020 Sep;67(9):e28557. doi: 10.1002/pbc.28557. Epub 2020 Jul 16. Pediatr Blood Cancer. 2020. PMID: 32672895 Free PMC article. No abstract available.
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Vega-García N, Perez-Jaume S, Esperanza-Cebollada E, Vicente-Garcés C, Torrebadell M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderón CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón Martinez-Gallo M, Muñoz L, Velasco MR, García-Morin M, Català A, Pascual A, Velasco P, Fernández JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana Á, Molinés A, Guerra-García P, Pérez-Martínez A, García-Abós M, Robles Ortiz R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives S, Ramírez-Orellana M, Camós M. Vega-García N, et al. Among authors: dapena jl. Front Pediatr. 2021 Feb 5;8:614521. doi: 10.3389/fped.2020.614521. eCollection 2020. Front Pediatr. 2021. PMID: 33614543 Free PMC article.
Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.
Fuster JL, Bautista F, González B, Fernández JM, Rives S, Dapena JL; Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Fuster JL, et al. Among authors: dapena jl. Clin Transl Oncol. 2021 Sep;23(9):1963-1966. doi: 10.1007/s12094-021-02590-0. Epub 2021 Mar 19. Clin Transl Oncol. 2021. PMID: 33742341 No abstract available.
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català A, Ruiz-Llobet A, Zapico-Muñiz E, Camós M, Rives S. Mesegué M, et al. Among authors: dapena jl. Hematol Oncol. 2021 Dec;39(5):687-696. doi: 10.1002/hon.2914. Epub 2021 Aug 16. Hematol Oncol. 2021. PMID: 34397119
Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013.
Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Dapena JL, Rives S, Sevilla J, Menárguez López Á, Panesso Romero M, Montoya C, Vagace JM, Molina Hurtado JR, García-Morín M, García Abós M, Mendoza Sánchez MC, Lendínez F, Palomo Moraleda P, Tallón M, González B, Urrutia E, Serna JV, Peláez Pleguezuelos I, Martínez Merino M, Ramos Elbal E, Orellana E, Benítez Muñoz H, Berrueco R. Ruiz-Llobet A, et al. Among authors: dapena jl. J Thromb Haemost. 2022 Jun;20(6):1390-1399. doi: 10.1111/jth.15699. Epub 2022 Mar 27. J Thromb Haemost. 2022. PMID: 35289066 Free article.
30 results